Radioactive 'Smart Bomb' targets Hard-to-Treat cancers in early trial
NCT ID NCT07020117
First seen Oct 01, 2025 · Last updated Jun 23, 2026 · Updated 33 times
Summary
This early-phase trial is testing a new radioactive drug that seeks out a protein called Nectin-4 found on many cancer cells. The drug delivers a dose of radiation directly to the tumor, aiming to destroy it while sparing healthy tissue. About 150 adults with advanced bladder, breast, lung, cervical, colorectal, or head and neck cancers that have not responded to prior treatments will receive the drug. The main goals are to find the safest dose and to see if the drug can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
BAMF Health
RECRUITINGGrand Rapids, Michigan, 49503, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Biogenix Molecular, LLC
RECRUITINGMiami, Florida, 33165, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
City of Hope
RECRUITINGDuarte, California, 91010, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Hoag Memorial Hospital Presbyterian
RECRUITINGIrvine, California, 92618, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Icahn School of Medicine at Mt. Sinai
RECRUITINGNew York, New York, 10029, United States
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
UPMC
RECRUITINGPittsburgh, Pennsylvania, 15232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
United Theranostics
RECRUITINGGlen Burnie, Maryland, 21061, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
University of Iowa
RECRUITINGIowa City, Iowa, 52242, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
[225Ac]Ac-AKY-1189 (a radioactive drug that targets Nectin-4 on cancer cells)
What this could lead to
If successful, this could lead to a new targeted radiation treatment for several types of advanced solid tumors that have stopped responding to other therapies.
What could go wrong
This is a very early (Phase 1b) and small study, so safety and effectiveness are not yet known. The radioactive drug may cause side effects, and it may not shrink tumors or improve survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.